Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug trial halted early – what we know

NCT ID NCT06881251

Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tested an experimental drug called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug could improve skin symptoms like redness, itching, and scaling better than a placebo. The trial was stopped early, so final results are limited, but the data may still help researchers understand how to treat eczema.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

256 people

The number who actually took part.

Started

Feb 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Chronic Atopic Dermatitis (AD), according to American Academy of Dermatology Consensus Criteria with onset of symptoms at least 1 year prior to the screening visit * Eczema Area and Severity Index (EASI) score greater than and equal to (\>=) 16 at the screening and baseline visits * Validated investigator global assessment for AD (vIGA-AD) score \>= 3 at the screening and baseline visits * \>= 10% body surface area (BSA) of AD involvement at the screening and baseline visits * Baseline Peak Pruritus Numeric(al) Rating Scale (PP-NRS) average score of \>=4 * Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, or inadequate response to systemic therapies (within 12 months before screening) * Participant has applied a moisturizer at least once daily for at least 7 days before the baseline visit Exclusion criteria: * Experienced primary efficacy failure (no response within 16 weeks) or an adverse event (AE) requiring discontinuation related to agents (eg, severe ocular surface disease, dupilumab-associated facial redness) inhibiting IL-4Rα, IL-4, and/or IL-13 signaling (eg, dupilumab, lebrikizumab, or tralokinumab) * Participant is pregnant or breastfeeding, or planning to become pregnant or breastfeed during the study * Active skin disease other than AD including eczema herpeticum, molluscum contagiosum, impetigo, psoriasis or has any other ongoing significant skin condition including skin infections, that, according to the investigator, could interfere with efficacy assessments * Current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances * Recent case of eczema herpeticum, herpes zoster within 8 weeks before screening, or history of recurrent eczema herpeticum * History of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (eg, untreated latent tuberculosis), recurrent urinary tract infection, fungal infection, mycobacterial infection, or open, draining, or infected skin wounds, or ulcers. * Diagnosed active parasitic infection or at high risk of parasitic infection, unless treated with antihelminth therapy prior to randomization * Had major surgery (eg, requiring general anesthesia and hospitalization), within 8 weeks before screening, or will not have fully recovered from surgery, or has such surgery planned during the time the participant is expected to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis, atopic

Contacts and locations

Locations

  • Arlington Center for Dermatology

    Arlington, Texas, 76011, United States

  • BR TRIALS Ensaios Clinicos e Consultoria Ltda

    São Paulo, 01236030, Brazil

  • CIPREC

    Buenos Aires, C1061AAS, Argentina

  • Care Clinic

    Katowice, 40 568, Poland

  • Center for Clinical Studies

    Houston, Texas, 77004, United States

  • Centre De Recherche Dermatologique Du Quebec Metropolitain

    Québec, Quebec, G1V 4X7, Canada

  • Centrum Badan Klinicznych PI House sp z o o

    Gdansk, 80 546, Poland

  • Centrum Medyczne All Med

    Krakow, 30 033, Poland

  • Centrum Medyczne Angelius Provita

    Katowice, 40-611, Poland

  • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna

    Lodz, 90-338, Poland

  • Ceti - Centro de Estudos Em Terapias Inovadoras

    Curitiba, 80.030-110, Brazil

  • Charite - Universitaetsmedizin Berlin (CCM)

    Berlin, 10117, Germany

  • Dawes Fretzin Clinical Research Group LLC

    Indianapolis, Indiana, 46250, United States

  • DeNova Research

    Chicago, Illinois, 60602, United States

  • Derma Internacional S A

    Buenos Aires, C1426, Argentina

  • Dermatology Research Institute Inc

    Calgary, Alberta, T2J 7E1, Canada

  • Dr. Chih ho Hong Medical

    Surrey, British Columbia, V3R 6A7, Canada

  • Eurofins bioskin GmbH

    Hamburg, 20095, Germany

  • Fachklinik Bad Bentheim

    Bad Bentheim, 48455, Germany

  • First OC Dermatology

    Fountain Valley, California, 92708, United States

  • Frontier Derm Partners CRO, LLC

    Mill Creek, Washington, 98012, United States

  • Fukuoka University Hospital

    Fukuoka, 814-0180, Japan

  • Fundacao do ABC Centro Universitario FMABC

    Santo André, 09060 870, Brazil

  • Grupo Dermatologico Y Estetico Pedro Jaen

    Madrid, 28002, Spain

  • Guys and St Thomas NHS Foundation Trust

    London, SE1 9RT, United Kingdom

  • Hamilton Research LLC

    Alpharetta, Georgia, 30022, United States

  • Hosp. Clinico Univ. de Santiago

    Santiago de Compostela, 15706, Spain

  • Hosp. Gral. Univ. Dr. Balmis

    Alicante, 03010, Spain

  • Hosp. Univ. San Cecilio

    Granada, 18016, Spain

  • Hosp. Univ. de Bellvitge

    LHospitalet de Llobregat, 08907, Spain

  • Hosp. Univ. de La Princesa

    Madrid, 28006, Spain

  • Hosp. de Manises

    Manises, 46940, Spain

  • Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP

    Ribeirão Preto, 14048 900, Brazil

  • Hospital De Clinicas De Porto Alegre

    Porto Alegre, 90035 903, Brazil

  • INAER - Investigacion en Alergias y Enfermedades Respiratorias

    Buenos Aires, C1425, Argentina

  • ISA - Interdisciplinary Study Association GmbH

    Berlin, 10789, Germany

  • Indiana Clinical Trial Center

    Plainfield, Indiana, 46168, United States

  • Innovaderm Research Inc.

    Montreal, Quebec, H2X 2V1, Canada

  • Instituto Brasil de Pesquisa Clinica

    Rio de Janeiro, 20241 180, Brazil

  • Instituto de Neumonologia y Dermatologia

    Buenos Aires, C1425, Argentina

  • Jitaikai Tachikawa dermatology clinic

    Tachikawa, 190 0023, Japan

  • Karma Clinical Trials Inc.

    St. John's, Newfoundland and Labrador, A1A 4Y3, Canada

  • Klinika Ambroziak Dermatologia

    Warsaw, 02 953, Poland

  • Kume Clinic

    Sakai, 593 8324, Japan

  • Lynderm Research Inc.

    Markham, Ontario, L3P 1X2, Canada

  • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden

    Dresden, 01307, Germany

  • Mie University Hospital

    Tsu, 514-8507, Japan

  • Nomura Dermatology Clinic

    Yokohama, 221 0825, Japan

  • Northwick Park Hospital

    London, HA13UJ, United Kingdom

  • Optima Research

    Boardman, Ohio, 44512, United States

  • Oregon Medical Research Center

    Portland, Oregon, 97201, United States

  • Osaka Habikino Medical Center

    Habikino, 583 8588, Japan

  • Progressive Clinical Research

    San Antonio, Texas, 78213, United States

  • Queens Square Medical Facilities

    Yokohama, 220 6208, Japan

  • Red River Research Partners LLC

    Fargo, North Dakota, 58103, United States

  • Royal London Hospital

    London, E1 1BB, United Kingdom

  • Royalderm Agnieszka Nawrocka

    Warsaw, 02962, Poland

  • Salford Royal Hospital

    Salford, M6 8HD, United Kingdom

  • Sapporo Skin Clinic

    Sapporo, 060 0063, Japan

  • Shirasaki Dermatology Clinic

    Takaoka Shi, 933-0871, Japan

  • SimcoDerm Medical and Surgical Dermatology Centre

    Barrie, Ontario, L4M 7G1, Canada

  • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna

    Krakow, 30-002, Poland

  • Studienzentrum Dr Schwarz Germany

    Langenau, 89129, Germany

  • Studienzentrum an der Hase GbR

    Bramsche, 49565, Germany

  • Teikyo University Hospital

    Itabashi Ku, 173 8606, Japan

  • The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust

    Kings Lynn, PE30 4ET, United Kingdom

  • Therapia Nova

    Warsaw, 01 595, Poland

  • Universitatsklinikum Dusseldorf

    Düsseldorf, 40225, Germany

  • Universitatsklinikum Frankfurt

    Frankfurt, 60596, Germany

  • University of California Los Angeles - Division of Dermatology

    Los Angeles, California, 90024, United States

  • WroMedica I Bielicka A Strzalkowska s c

    Wroclaw, 51 685, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.